Big Moving Stock chart patterns and volume.
The Hot Industries
Health Care Plans 5
Aerospace/Defense Products & Services 2
The Hot Sectors
Industrial Goods 3
ARIA Ariad Pharmaceuticals Inc.
ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. The company focuses on commercializing Iclusig (ponatinib), a cancer medicine; and developing additional molecularly targeted therapies to treat patients with blood cancers and solid tumors. Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States for the treatment of adult patients with chronic, accelerated, or blast phase chronic myeloid leukemia, who are resistant or intolerant to prior TKI therapy, as well as for the treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, who are resistant or intolerant to prior TKI therapy. Its product pipeline consists of AP26113, an investigational dual inhibitor of anaplastic lymphoma kinase, which is being studied in a phase I/II clinical trial in patients with advanced solid tumors comprising non-small cell lung cancer; Ridaforolimus, an investigational mTOR inhibitor, which is being studied in multiple clinical trials in patients with various types of cancers; and AP1903, a small-molecule dimerizer drug. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has collaboration and license agreement with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus, for use in cancer; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.
First Week of ARIA March 20th Options Trading23 Jan 2015, 9:43 amFirst Week of ARIA March 20th Options Trading
ARIAD's Iclusig Endorsed by EC for All Approved Indications - Analyst Blog21 Jan 2015, 12:00 pmARIAD Pharmaceuticals, Inc. (ARIA) announced that the European Commission endorsed the CHMP's recommendation on the use of Iclusig in its approved indications.
ARIAD Reveals 2015 Strategic Objectives, Updates on Pipeline - Analyst Blog14 Jan 2015, 4:05 pmARIAD Pharmaceuticals, Inc. (ARIA) announced its key strategic objectives for 2015 and its aim to increase R&D and expand business development activities.
Credit Suisse's 4 Healthcare Stocks To Avoid11 Jan 2015, 11:15 amIn a recent report, analysts at Credit Suisse outlined their 2015 outlook for healthcare stocks. Here’s a breakdown of their top stocks to avoid in 2015. 1. United Therapeutics Corp (NASDAQ: UTHR ): Analysts ...
February 27th Options Now Available For ARIAD Pharmaceuticals (ARIA)8 Jan 2015, 11:02 amFebruary 27th Options Now Available For ARIAD Pharmaceuticals (ARIA)
Is Ariad Pharmaceuticals (ARIA) Stock a Solid Choice Right Now? - Tale of the Tape2 Jan 2015, 8:34 amIs Ariad Pharmaceuticals (ARIA) Stock a Solid Choice Right Now? - Tale of the Tape
ARIAD & Angelini Team Up to Commercialize Iclusig in Europe - Analyst Blog31 Dec 2014, 12:35 pmARIAD Pharmaceuticals, Inc. (ARIA) announced that it has granted exclusive rights to privately-held pharmaceutical company Angelini Pharma to commercialize Iclusig in Central and Eastern Europe.
ARIA Widens Sales Turf, NRX Skips A Beat, NDRM Triples On Parkinson''s Study30 Dec 2014, 9:49 pmARIA Widens Sales Turf, NRX Skips A Beat, NDRM Triples On Parkinson''s Study
ARIA Widens Sales Turf, NRX Skips A Beat, NRDM Triples On Parkinson's Study30 Dec 2014, 9:48 pmARIA Widens Sales Turf, NRX Skips A Beat, NRDM Triples On Parkinson's Study
ARIA: Insiders vs. Shorts29 Dec 2014, 1:26 pmThe most recent short interest data was recently released by the NASDAQ for the 12/15/2014 settlement date, and ARIAD Pharmaceuticals, Inc. (NASD: ARIA) is one of the most shorted stocks of the Russell 3000, based on 6.18 "days to cover" versus the median component at 5.32. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover ...